



Original article

The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy

Yini He^a, Na Ao^b, Jing Yang^b, Xiaochen Wang^c, Shi Jin^b, Jian Du^{b,*}^a Department of General Practice, The First Hospital of China Medical University, Shenyang, Liaoning, China^b Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China^c Department of Endocrinology, The People's Hospital of Liaoning Province, Shenyang, Liaoning, China

ARTICLE INFO

Article history:

Received 25 February 2019

Accepted 25 June 2019

Available online 24 September 2019

Keywords:

GLP-1

AMPK

NAFLD

Hepatic steatosis

Treatment

ABSTRACT

Introduction and objectives: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing. Previous studies indicated that Liraglutide, glucagon-like peptide-1 analogue, could regulate glucose homeostasis as a valuable treatment for Type 2 Diabetes. However, the precise effect of Liraglutide on NAFLD model in rats and the mechanism remains unknown. In this study, we investigated the molecular mechanism by which Liraglutide ameliorates hepatic steatosis in a high-fat diet (HFD)-induced rat model of NAFLD in vivo and in vitro.

Materials and methods: NAFLD rat models and hepatocyte steatosis in HepG2 cells were induced by HFD and palmitate fatty acid treatment, respectively. AMPK inhibitor, Compound C was added in HepG2 cells. Autophagy-related proteins LC3, Beclin1 and Atg7, and AMPK pathway-associated proteins were evaluated by Western blot and RT-PCR.

Results: Liraglutide enhanced autophagy as showed by the increased expression of the autophagy markers LC3, Beclin1 and Atg7 in HFD rats and HepG2 cells treated with palmitate fatty acid. In vitro, The AMPK inhibitor exhibited an inhibitory effect on Liraglutide-induced autophagy enhancement with the decreased expression of LC3, Beclin1 and Atg7. Additionally, Liraglutide treatment elevated AMPK levels and TSC1, decreased p-mTOR expression.

Conclusions: Liraglutide could upregulate autophagy to decrease lipid over-accumulation via the AMPK/mTOR pathway.

© 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

At present, non-alcoholic fatty liver disease (NAFLD) is prevalent and keeps rising. In developed countries, about 80% of adults with obesity or diabetes has been suffering from NAFLD [1,2], and the NAFLDs has relatively higher risk of liver fibrosis and liver cancer [3,4]. It is generally believed that NAFLD is closely related to insulin resistance, obesity, diabetes, dyslipidemia, and other metabolic syndromes that clinically manifest in the liver [5–7]. NAFLD includes simple fatty liver, fatty hepatitis, and fatty liver-related cirrhosis, which can develop into liver cancer [8]. NAFLD has also been considered as a high risk to induce cardiovascular and cerebrovascular diseases [9].

It is well understood that insulin resistance leads to excessive intake of free fatty acids (FFA) caused by steatosis. In addition, other factors, including oxidative stress injury, lipid peroxidation and abnormal cytokines, can cause local inflammatory changes that cause steatohepatitis in the hepatic lobules [10]. While this ‘two-hit’ hypothesis is currently widely accepted, NAFLD pathogenesis is not yet fully understood [11]. Excessive lipid deposition in the liver has been considered the primary factor that induces liver lipotoxicity [12–14]. Additionally, autophagy has been closely associated with intrahepatic lipid deposition. Previous studies have shown that autophagy degrades fat in hepatocytes as a relatively fixed process of auto-catabolism [15–17]. Autophagy can also promote “self-digestion” of accumulated, failing protein aggregates and defective organelles within the cell to maintain stability in the intracellular environment [18,19]. Lipid drops (LDs), which are biodegradation substrates, can be annexed and decomposed by the lysosomal pathway to maintain balanced intracellular lipid metabolism. Decreased intrahepatic autophagic activity, both *in vitro* and *in vivo*, can induce excessive lipid deposition [20].

* Corresponding author at: Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
E-mail addresses: cmu1hyn@163.com, duj2019@126.com (J. Du).

Evidence indicates that glucagon like peptide-1 (GLP-1) protects the liver from cell apoptosis induced by fatty acids through promoting autophagy and suppressing dysfunctional endoplasmic reticulum stress [21,22]. AMP-activated protein kinase (AMPK) is a cellular energy sensor that plays a key role in metabolic disorders and cancer [23]. The AMPK pathway is thought to critically regulate autophagy [24]. More specifically, AMPK activation can inhibit metabolic pathways and activate catabolic pathways to promote effective energy expenditure, which consequently improves how cells adapt to metabolic stress, resulting in increased cell survival [23,25].

Previous studies showed that GLP-1 improves hepatocyte steatosis by inducing autophagy through activating AMPK [26] in mice, suggesting that AMPK protects pancreatic β -cells from high glucose [27]. This evidence provides a new direction for targeting GLP-1 to prevent further deterioration of hepatic steatosis in NAFLD patients. However, the effect of GLP-1 analogs on high-fat diet (HFD)-induced NAFLD in rats has not been investigated. Further, the mechanism underlying liraglutide-induced autophagy is currently unknown. In the current study, we confirmed that liraglutide enhances autophagy in liver tissue and improves hepatic steatosis in a HFD-induced rat model of NAFLD. In addition, we provide evidence supporting the potential mechanism involving activation of the AMPK-mTOR pathway in liver homeostasis.

2. Materials and methods

2.1. Animals

Male Sprague–Dawley rats ($n=50$, 5 weeks of age, approximately 100 g) obtained from the Laboratory Animal Center of China Medical University were used to establish the NAFLD model. All rats were acclimated for one week prior to experimentation according to a previous protocol published [28]. Briefly, two initial groups of rats were randomly separated. The normal control (NC) group ($n=13$) was fed chow containing 62% carbohydrates, 10% fat, and 28% protein; the HFD group ($n=37$) was fed chow containing 34% carbohydrates, 52% fat, and 14% protein. Five rats from each group were randomly selected to confirm successful establishment of NAFLD after 12 weeks of feeding. (All animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health.)

Rats in the HFD group were randomly subdivided into four groups: HFD, 50 L, 100 L, and 200 L ($n=8$ in each group). Rats in the HFD group were continually fed a HFD and were given 0.5 ml/kg of normal saline as needed. Rats in the 50 L, 100 L, and 200 L groups continued to receive HFD with different doses of liraglutide (L) (50, 100, or 200 $\mu\text{g/kg}$) (Victoza, Novo-Nordisk A/S, Denmark), respectively. The rats in the NC group ($n=8$) continued to receive normal chow and were injected with 0.5 ml/kg of normal saline. Saline and liraglutide were injected subcutaneously at 8:00 am and 8:00 pm every day for 4 weeks.

2.2. Cell culture and treatment

HepG2 cells were cultured at 37 °C in a humidified chamber with 5% CO₂ and maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco) containing 10% heat-inactivated fetal bovine serum (FBS, Gibco). There were a total of six cell culture groups: Control group treated with serum-free bovine serum albumin (BSA; Sigma–Aldrich, USA) medium; PA group treated with or without 400 M palmitate fatty acid (PA) for 24 h; and experimental groups treated with 400 M PA and either 10, 50, 100, or 500 nmol/L liraglutide for 24 h, respectively. These cells were divided into four groups:

normal HepG2 cells (BSA), treated with PA (PA), treated with PA and liraglutide (100G), and Compound C for 30 min and then treated with PA and liraglutide (100G + C). Compound C is an AMPK pathway inhibitor.

2.3. Western blot analysis

Liver specimens and whole-cell extracts were homogenized and centrifuged in RIPA buffer (Beyotime Institute of Biotechnology, China) containing a protease inhibitor cocktail with 1 mmol/L phenylmethanesulfonyl fluoride (Beyotime) on ice. Protein lysates were quantified using the BCA assay as previously described [28] (Pierce, USA). 50 μg of protein for each sample were separated by 8–10% SDS-PAGE and transferred to PVDF membranes (Millipore, USA). The membranes were blocked with 5% BSA and then incubated with primary antibodies against microtubule-associated protein LC3, Beclin1, AMPK, phosphorylated (p)-AMPK, TSC1, mTOR, and p-mTOR (all of which were used at 1:1000 and purchased from Cell Signaling Technology, USA) and GAPDH (used at 1:1000; Santa Cruz, CA, USA) at 4 °C overnight. The horseradish peroxidase-conjugated anti-rabbit, anti-goat, or anti-mouse secondary antibodies (1:5000, all from Santa Cruz Biotechnology, Inc.) were added at room temperature for 2 h after 3 washes (10 min each). The immunological complexes were visualized with Micro Chemi 4.2 (DNR Bio-Imaging Systems Ltd., Jerusalem, Israel). Quantity One Software (Bio-Rad, USA) was used to quantify the protein band intensity.

2.4. Real-time RT-PCR

Total RNA from the frozen liver specimens (100 mg) and cell cultures were isolated using Trizol reagent (Takara Biotechnology Co., Ltd.). The PrimeScript™ RT reagent kit was used to synthesize cDNA (Takara Biotechnology Co., Ltd., Dalian, China).

Real-time RT-PCR analysis was performed with a Thermal Cycler Dice Real Time detection System (Takara Bio Inc., Japan) using the SYBR Premix Ex Taq II kit (Tli RNaseH Plus) (Takara Biotechnology Co., Ltd.). Gene-specific primers for GFAP and GAPDH were purchased from Takara Biotechnology Co., Ltd. The following PCR protocol was used for all genes: reverse transcription step for 15 min at 37 °C, then denaturation at 85 °C for 5 s, 4 °C for 7 min, followed by an additional 40 cycles of amplification and quantification (5 s at 95 °C; 30 s at 60 °C; 30 s at 60 °C). mRNA expression was normalized to GAPDH as a housekeeping gene. The primers were designed (Primer Premier 5.0) and synthesized (Takara Biotechnology Co., Ltd. Dalian, China). For each gene, the relative change of mRNA in the samples was calculated by subtracting GAPDH Ct values from Ct values for the gene of interest using the $2^{-\Delta\Delta\text{Ct}}$ method.

2.5. Electron microscopy

For transmission electron microscopy (TEM), liver specimens were fixed with 2.5% glutaraldehyde in a 0.1 M sodium cacodylate, pH 7.4, buffer at 4 °C and then minced into small (1 mm³) fragments. After washing with 0.1 M phosphate buffered saline (PBS) three times for 15 min each, the liver tissue samples were fixed in 1% osmium tetroxide (OSO₄) for 1 h, followed by washes in 0.1 M PBS. Liver tissues were gradually dehydrated in ethanol solutions of 20%, 50%, 70% and 90% and embedded in Epon 812 epoxy resin before ultrathin sectioning. The ultrastructure of the sections was visualized using a JEM-1200EX electron microscope (JEOL Co., Japan) in the TEM laboratory of China Medical University.

2.6. Hematoxylin and eosin (HE) Staining

The liver tissues were fixed at 5 mm from the edge of the right lobe of the liver and immersed in 4% paraformaldehyde. Then the tissues were dehydrated, waxed, embedded, and sliced for HE staining. Samples were dewaxed, benzenes were removed, hydrated, hematoxylin stained, washed, eosin stained, dehydrated, and imaged. According to the 2010 guidelines for the diagnosis and treatment of NLF liver histopathological sections were scored based on the NAS system (0 to 8 points): (1) hepatocellular steatosis: 0 points (<5%); 1 point (5–33%); 2 points (34–66%); 3 points (>66%); (2) Inflammation within the lobules (inflammatory necrosis at 20-fold microscopy): 0 points (none), 1 point (<2), 2 points (2–4), 3 points (>4); (3) liver cell ballooning: 0 points, no; 1 point, rare; 2 points, more common.

2.7. Statistical analysis

All data are expressed as the mean $\pm$ standard deviation (SD) and calculated with one-way analysis of variance (ANOVA) followed by

a Newman–Keuls post-hoc test (SPSS 17.0). Results of comparisons were considered significantly different if the p value was <0.05.

3. Results

3.1. Liraglutide improves hepatic histology during NAFLD development

After 16 weeks of HFD or normal chow diet we examined the histological features of the livers from NAFLD and NC mice. The liver surfaces were greyish yellow and the edges were blunt and thick in the HFD group compared to the NC group, in which the livers were bright red with sharp edges. Liraglutide dose-dependently ameliorated the pathological hepatic histology in the HFD group (Fig. 1A–E).

As shown in Fig. 2A–E, liraglutide improved the hepatic histology by significantly reducing both fatty droplets and inflammatory foci number. NAS quantification of liver sections further confirmed the beneficial effects of liraglutide treatment on hepatic histology (Table 1). Compared to the NC rats, the HFD rats had more




Fig. 1. The general changes in liver tissue after 16 weeks of HFD. A. NC group, B. HFD control group, C. 50 L group: low dose liraglutide intervention group (50 μ g/kg), D. 100 L group: middle dose liraglutide intervention group (100 μ g/kg), E. 200 L group: high-dose liraglutide intervention group (200 μ g/kg).




Fig. 2. Histopathological changes in rat livers 16 weeks after HFD. A. Histopathological changes ($\times 200$); B. Rat liver histopathological NAS scores; C. 50 L group: low dose liraglutide intervention group (50 μ g/kg), D. 100 L group: middle dose liraglutide intervention group (100 μ g/kg), E. 200 L group: high-dose liraglutide intervention group (200 μ g/kg).

Table 1

The NAS scores of hepatic pathological sections after 16 weeks of HFD

Group	Steatosis	Inflammatory necrosis	Balloon-like changes
NC	0.28 ± 0.48	0.29 ± 0.48	0
HF	2.80 ± 0.38 [*]	1.85 ± 0.38 [*]	1.57 ± 0.53 [*]
50L	1.29 ± 0	1.00 ± 0.00 [#]	0.85 ± 0.38 [#]
100L	1.13 ± 0.53 [#]	0.71 ± 0.56 [#]	0.42 ± 0.54 [#]
200L	0.37 ± 0	0.25 ± 0.52 [#]	0.13 ± 0.35 [#]

^{*} Compared to NC group, $P < 0.05$ [#] compared to HF group, $P < 0.05$

hepatocellular steatosis ($P < 0.05$), but liraglutide dose-dependently and significantly decreased steatosis, inflammation, and ballooning in the HFD group compared to the NC group ($P < 0.05$).

3.2. Liraglutide improves autophagy in the NAFLD rat model

We used electron microscopy to measure autophagosomes in each group. We found that the number of autophagosomes in the HFD group was significantly lower compared to the NC group. Liraglutide treatment dose-dependently increased the number of autophagocytic bodies in the HFD group compared to the NC group (Fig. 3A and B).

To further determine whether liraglutide improves autophagy in HFD-induced NAFLD rats, we measured the expression of autophagy-related proteins, LC3, Beclin1 and Atg7, in liver tissues. We found that LC3, Beclin1 and Atg7 mRNA levels and protein expression were significantly reduced in the HFD group and that liraglutide treatment dramatically increased expression of these autophagy markers (Fig. 4A–F).

3.3. Liraglutide improves autophagy in HepG2 cell in vitro

We measured mRNA and protein expression of the autophagy-related proteins, LC3, Beclin1 and Atg7, in HepG2 cells following PA treatment. In the PA group, mRNA and protein expression of LC3, Beclin1 and Atg7 were significantly lower compared to the BSA group ($P < 0.01$). However, liraglutide dose-dependently increased the mRNA and protein levels of LC3, Beclin1 and Atg7 relative to the PA group ($P < 0.01$) (Fig. 5A–F).

3.4. The effect of liraglutide on autophagy in HepG2 cells following AMPK pathway inhibition

To investigate whether the AMPK pathway was involved in liraglutide-mediated improvement of autophagy after PA treatment, we measured protein levels of LC3, Beclin1 and Atg7 in




Fig. 3. Ultrastructure of hepatocytes observed by electron microscopy. A. NC group, B. HF group, C. 50L group: low dose liraglutide intervention group (50 $\mu\text{g/kg}$), D. 100L group: middle dose liraglutide intervention group (100 $\mu\text{g/kg}$), E. 200L group: high-dose liraglutide intervention group (200 $\mu\text{g/kg}$). N, nucleus; LD, lipid droplet; $\rightarrow$, autophagy body.




Fig. 4. Liraglutide reversed the decrease in autophagy related proteins in HFD-induced NAFLD rats. A and B. LC3II mRNA expression and LC3II/LC3I protein were assessed by real-time RT-PCR and Western blot, respectively. C and D. Beclin1 mRNA and protein expression were detected by real-time RT-PCR and Western blot, respectively. E and F. Atg7 mRNA and protein expression were measured by real-time RT-PCR and Western blot, respectively.

HepG2 cells. The results showed that the levels of LC3, Beclin1 and Atg7 were significantly higher in the liraglutide intervention group (100G group) compared to the PA group ($P < 0.01$). However, LC3, Beclin1 and Atg7 levels were significantly lower in the inhibition group (100G+C) containing Compound C, PA (400 mmol/L) and liraglutide (100 nmol/L), compared to the 100G group ($P < 0.01$) (Fig. 6A–C).

3.5. Effects of liraglutide on AMPK pathway-associated proteins following AMPK pathway inhibition

We measured expression of AMPK pathway-associated proteins to confirm that liraglutide-mediated autophagy induced by PA could be reversed by inhibiting the AMPK pathway. As shown in Fig. 6, the levels of p-AMPK/AMPK, TSC1, p-mTOR/mTOR were




Fig. 5. Liraglutide reversed the decrease in autophagy related proteins in HepG2 cells. A and B. LC3II mRNA and protein expression were assessed by real-time RT-PCR and Western blot, respectively. C and D. Beclin1 mRNA and protein expression were detected by real-time RT-PCR and Western blot, respectively. E and F. Atg7 mRNA and protein expression were measured by real-time RT-PCR and Western blot, respectively.




Fig. 6. The effect of liraglutide on autophagy in HepG2 cells in the presence of the AMPK pathway inhibitor. A. Expression of LC3II/LC3I detected by Western blot with or without the AMPK pathway inhibitor. B. Expression of Beclin1 detected by Western blot with or without the AMPK pathway inhibitor. C. Expression of Atg7 detected by Western blot with or without the AMPK pathway inhibitor.

decreased ($P < 0.01$) in the PA group (400 $\mu\text{mol/L}$ PA) compared to the control group (BSA group). Furthermore, the levels of p-AMPK/AMPK, TSC1, and p-mTOR/mTOR were increased in the liraglutide intervention group (100G group) compared to the PA group ($P < 0.05$). The levels of p-AMPK/AMPK, TSC1, p-mTOR/mTOR were significantly lower than those in the 100G group compared to the inhibition group (100 G+C) containing Compound C, PA (400 $\mu\text{mol/L}$), and liraglutide (100 nmol/L) ($P < 0.01$) (Fig. 7A–C).

4. Discussion

The prevalence of NAFLD has increased worldwide, affecting both adults and children. Liraglutide, a GLP-1 analog, has been reported to decrease lipid deposition and inflammation in hepatocytes [29,30]. However, few studies have investigated whether liraglutide can improve hepatic lipid accumulation in NAFLD. In the current study, we used an established rat model of HFD-induced NAFLD and demonstrated that liraglutide significantly decreased the number of autophagosomes. Liraglutide treatment dose-dependently improved autophagy, which was confirmed by measuring expression of autophagy-related proteins *in vivo* and *in vitro*. More importantly, the AMPK pathway inhibitor, Compound C, reversed liraglutide's effects on autophagy following PA treatment *in vitro*, which suggests that liraglutide-induced autophagy is mediated by the AMPK signaling pathway.

Autophagy is an intracellular pathway that maintains normal cellular function by promoting turnover of long-lived proteins [31]. Studies have demonstrated that enhanced autophagy can rescue pancreatic β -cells from glucotoxicity, and inhibition of autophagy augments caspase-3 activation [32], suggesting that autophagy might protect against Type 2 Diabetes. Previous evidence indicated that autophagy is suppressed in the presence of hyper-insulinemia induced by HFD in mice [33], which was consistent with our results; however, we note that we used a different animal model in our study. Our results indicate that autophagy was significantly decreased in the NAFLD rat model, since the autophagy-related proteins, LC3, Beclin1 and Atg7, were significantly reduced at both the mRNA and protein levels. We also noticed that autophagy-related protein levels were decreased in palmitate-induced lipotoxicity in HepG2 cells *in vitro*, which mimics the pathogenic features of the NAFLD model *in vivo*.

Liraglutide, a GLP-1 analog, regulates β -cell mass via multiple pathways [34–36]. Liraglutide was proven to decrease lipid accumulation in the steatotic LO2 cell model [37] and protect pancreatic β -cells from high glucose by enhancing autophagy via AMPK [26]. It is also known that GLP-1 exerts protective effects on hepatic steatosis [38]. In the present study, we found that the general appearance, histopathological changes, and the number of autophagic bodies in the livers of NAFLD rats improved after liraglutide treatment. Further evidence showed that liraglutide dose-dependently increased the expression of autophagy-related proteins in rats fed a HFD and in HepG2 cells treated with PA. These results suggest that GLP-1 ameliorates HFD induced NAFLD by activating autophagy.

Existing research shows that the AMPK/mTOR pathway regulates downstream signaling to trigger autophagy [39]. AMPK could negatively affect liraglutide-induced increases in cell viability and autophagy to protect insulin-1 pancreatic β -cells from glucotoxicity in rats [27]. In addition, AMPK/mTOR signaling was involved in hepatic lipid metabolism induced by GLP-1 [26].

Our data revealed that Compound C, an AMPK pathway inhibitor, reversed the enhanced autophagy induced by liraglutide in HepG2 cells treated with PA, which suggests that liraglutide intervention activates AMPK and up-regulates autophagy. Thus, we conclude




Fig. 7. Effects of liraglutide on AMPK pathway-associated proteins in the presence of the AMPK pathway inhibitor. A. Expression of p-AMPK/AMPK detected by Western blot. B. Expression of TSC1 detected by Western blot. C. Expression of p-mTOR/mTOR detected by Western blot.

that the AMPK pathway plays an important role in regulating autophagy induced by liraglutide.

In conclusion, the current study demonstrates that liraglutide can improve hepatic steatosis via activating the AMPK pathway. These data suggest that GLP-1 may play a protective role in several models of NAFLD and that modulation of AMPK could be a potential target for lipid metabolic disorders.

Abbreviations

AMPK	adenosine 5'-monophosphate (AMP)-activated protein kinase
Atg7	autophagy related gene 7
Beclin1	heterozygous disruption of beclin1
cAMP	cyclic adenosine monophosphate
GLP-1	glucagon-like peptide-1

LC3	micro-tubule-associated protein1 light chain 3
mTOR	the mammalian target of rapamycin
NAFLD	nonalcoholic fatty liver disease
PA	palmitate
T2DM	type 2 diabetes mellitus
TSC1	tuberous sclerosis-1

Author's contribution

Description of author roles in manuscript creation: Jian Du designed the experiment. Yini He, Na Ao and Jing Yang performed the performed experiments, Xiaochen Wang and Shi Jin processed the data, Yini He wrote the paper, and Jian Du modified the paper.

Funding

The Science and Technology Agency of Liao Ning (20170520272); The Hall Education of Liaoning (L2015567) (LQNK201715).

Conflict of interest

All authors declare no conflicts of interest.

Acknowledgments

We are grateful for the reagents and technical support provided by the Center Laboratory of The First Hospital and The Laboratory Animal Center of China Medical University.

References

- [1] Tateishi R, Koike K. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). *Nihon Shokakibyo Gakkai Zasshi* 2017;114(5):813–8. Epub 2017/05/10.
- [2] Bellentani S. The epidemiology of non-alcoholic fatty liver disease. *Liver Int* 2017;37(Suppl. 1):S1–4. Epub 2017/01/05.
- [3] Cazanave S, Podtelezchnikov A, Jensen K, Seneshaw M, Kumar DP, Min HK, et al. The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. *Sci Rep* 2017;7(1):17193. Epub 2017/12/10.
- [4] Del Campo JA, Gallego-Duran R, Gallego P, Grande L. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). *Int J Mol Sci* 2018;19(3). Epub 2018/03/23.
- [5] Pan S, Hong W, Wu W, Chen Q, Zhao Q, Wu J, et al. The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm. *Medicine (Baltimore)* 2017;96(2):e5809. Epub 2017/01/13.
- [6] Rausch JC, Lavine JE, Chalasani N, Guo X, Kwon S, Schwimmer JB, et al. Genetic variants associated with obesity and insulin resistance in hispanic boys with nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2018. Epub 2018/02/23.
- [7] Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. *Cleve Clin J Med* 2008;75(10):721–8. Epub 2008/10/23.
- [8] Review T, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *J Clin Gastroenterol* 2014;48(6):467–73. Epub 2014/06/13.
- [9] Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? *Semin Liver Dis* 2012;32(1):14–21. Epub 2012/03/16.
- [10] Ogbomo SM, Shi W, Wagh NK, Zhou Z, Brusnahan SK, Garrison JC. 177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable linkers: synthesis, characterization and preliminary in vivo investigation in a pancreatic cancer model. *Nucl Med Biol* 2013;40(5):606–17. Epub 2013/04/30.
- [11] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism* 2016;65(8):1038–48. Epub 2016/01/30.
- [12] Perla FM, Prelati M, Lavorato M, Visicchio D, Anania C. The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease. *Children (Basel)* 2017;4(6). Epub 2017/06/08.
- [13] Li M, Xu C, Shi J, Ding J, Wan X, Chen D, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. *Gut* 2017. Epub 2017/09/08.
- [14] Danford CJ, Sanchez JE, Corey KE. Managing the burden of non-NASH NAFLD. *Curr Hepatol Rep* 2017;16(4):326–34. Epub 2018/03/06.
- [15] Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. *Nature* 2009;458(7242):1131–5. Epub 2009/04/03.
- [16] Maetzel D, Sarkar S, Wang HY, Abi-Mosleh L, Xu P, Cheng AW, et al. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick type C patient-specific iPS cells. *Stem Cell Rep* 2014;2(6):866–80.
- [17] Czaja MJ. Function of autophagy in nonalcoholic fatty liver disease. *Dig Dis Sci* 2016;61(5):1304–13. Epub 2016/01/05.
- [18] Feng Y, Yao Z, Klionsky DJ. How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. *Trends Cell Biol* 2015;25(6):354–63. Epub 2015/03/12.
- [19] Hiebel C, Behl C. The complex modulation of lysosomal degradation pathways by cannabinoid receptors 1 and 2. *Life Sci* 2015;138:3–7. Epub 2015/04/25.
- [20] Li Z, Wang J, Yang X. Functions of autophagy in pathological cardiac hypertrophy. *Int J Biol Sci* 2015;11(6):672–8. Epub 2015/05/23.
- [21] Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). *Curr Drug Discov Technol* 2007;4(2):133–40. Epub 2007/08/19.
- [22] Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. *J Clin Gastroenterol* 2012;46(4):272–84. Epub 2012/03/08.
- [23] Hardie DG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. *Biochem Soc Trans* 2011;39(1):1–13. Epub 2011/01/27.
- [24] Zhao B, Qiang L, Joseph J, Kalyanaraman B, Viollet B, He YY. Mitochondrial dysfunction activates the AMPK signaling and autophagy to promote cell survival. *Genes Dis* 2016;3(1):82–7. Epub 2017/01/10.
- [25] Asiedu MN, Dussor G, Price TJ. Targeting AMPK for the alleviation of pathological pain. *EXS* 2016;107:257–85. Epub 2016/11/05.
- [26] He Q, Sha S, Sun L, Zhang J, Dong M. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. *Biochem Biophys Res Commun* 2016;476(4):196–203. Epub 2016/05/22.
- [27] Miao X, Gu Z, Liu Y, Jin M, Lu Y, Gong Y, et al. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 beta-cells under high glucose conditions. *Peptides* 2018;100:127–39. Epub 2017/07/18.
- [28] Ao N, Yang J, Wang X, Du J. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. *Hepatol Res* 2016;46(4):343–53. Epub 2015/07/07.
- [29] Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. *PLoS ONE* 2012;7(12):e50117. Epub 2012/12/14.
- [30] Kim YO, Schuppan D. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. *Am J Physiol Gastrointest Liver Physiol* 2012;302(8):G759–61. Epub 2012/03/03.
- [31] Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol* 2010;12(3):213–23. Epub 2010/02/23.
- [32] Han D, Yang B, Olson LK, Greenstein A, Baek SH, Claycombe KJ, et al. Activation of autophagy through modulation of 5'-AMP-activated protein kinase protects pancreatic beta-cells from high glucose. *Biochem J* 2010;425(3):541–51. Epub 2009/11/12.
- [33] Liu HY, Han J, Cao SY, Hong T, Zhuo D, Shi J, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. *J Biol Chem* 2009;284(45):31484–92. Epub 2009/09/18.
- [34] Kuhre RE, Holst JJ, Kappe C. The regulation of function, growth and survival of GLP-1-producing L-cells. *Clin Sci (Lond)* 2016;130(2):79–91. Epub 2015/12/08.
- [35] Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, et al. A comparison of the effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized controlled trial Sapporo Athero-Incretin Study 2 (SAIS2). *PLoS ONE* 2015;10(8):e0135854. Epub 2015/08/19.
- [36] Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. *Horm Metab Res* 2004;36(11–12):811–21. Epub 2005/01/19.
- [37] Zhou SW, Zhang M, Zhu M. Liraglutide reduces lipid accumulation in steatotic L02 cells by enhancing autophagy. *Mol Med Rep* 2014;10(5):2351–7. Epub 2014/09/19.
- [38] Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. *J Diabetes Complicat* 2013;27(4):401–6. Epub 2013/01/29.
- [39] He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet* 2009;43:67–93. Epub 2009/08/06.